Serrano, César <br/><br/>
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.  [electronic resource] 

 -  British journal of cancer  03 2019 
 - 612-620 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/s41416-019-0389-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>CHO Cells<br/>Clinical Trials, Phase II as Topic<br/>Cricetulus<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gastrointestinal Neoplasms--drug therapy<br/>Gastrointestinal Stromal Tumors--drug therapy<br/>Humans<br/>Imatinib Mesylate--pharmacology<br/>Mice<br/>Mice, Nude<br/>Mutation<br/>Phenylurea Compounds--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-kit--antagonists & inhibitors<br/>Pyridines--pharmacology<br/>Sunitinib--pharmacology<br/>Xenograft Model Antitumor Assays